Biocon’s novel drug pipeline which has an ophthalmology molecule, QPI-1007, is entering clinical trial phase. QPI-1007 is for ocular neuroprotection in NAION and acute angle closure glaucoma. In mid-December 2013, the company entered into a licensing and collaboration agreement for the development of a range of siRNA (small interfering RNA) based novel therapeutics with Quark Pharmaceuticals which was researching on QPI-1007.
USFDA rejected Sun Pharma Advanced Research Company’s Application for its new anti-glaucoma eye drops. The product is to be manufactured at Sun Pharmaceutical Industries’ Halol facility. USFDA has indicated that a satisfactory resolution of the current good manufacturing practice (cGMP) deficiencies at this facility is a prerequisite for the final approval of Xelpros.
Pharmaceuticals Export Promotion Council of India (Pharmexcil) recently launched online services to accept submission for Market Development Assistance (MDA) and Market Development Initiative (MDI) claims.This move is aimed at delivering not only hassle-free timely services to the members.
Nutech Mediworld, the world’s only human embryonic stem cell therapy centre based in India, announced that its human embryonic stem cell (hESC) technology developed by Dr Geeta Shroff has received 66th patent in Malaysia for the treatment of various medical conditions.
The technology differentiates itself from other stem cell therapies in three major ways. Firstly, it has universal application, i.e. anyone and everyone can take these cells without the need for matching. Secondly, it is available in a ready to use form with a shelf life of 6 months & can be transported easily. Thus is not clinic based. Thirdly, it has an easy non-invasive delivery mechanism and can be administered in the simple form of an injection. Due to these qualities it has the potential to be made readily available in pharmacies across the world, much like insulin.
[adsense:336x280:8701650588]
Apollo Children’s Hospital has recently performed surgeries on children using the da Vinci robot. Robotic procedures have proven to be highly precise and targeted. This technique provides advantages like quicker discharge time, minimal scarring, smaller incisions and less blood loss that conventional laparoscopy offers over open surgeries.
Parkinson's disease (PD) is a chronic and progressive disorder of the central nervous system that affects movement. It is often characterized by tremors. Researchers have now found a link between a class of drugs used to treat diabetes and protection against PD. The study published in PLOS Medicine.
(Business Wire India) Wipro Limited, a leading global information technology, consulting, and business process services company, today announced that it has been selected by DSM, a global, science based company active in health, nutrition and materials, as its strategic IT partner to provide Workplace Services.
Biogen and the Parkinson’s Institute and Clinical Center announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson’s disease (PD) and the creation of novel tools and programs that could accelerate research and the development of new PD treatments. The agreement will combine the unique clinical expertise and data of the Institute with Biogen’s focus on neurodegenerative disease and approach to clinical development.
Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today announced an exclusive license and collaboration agreement for the development and global commercialisation rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of EGFR mutation positive lung cancer. Under the terms of the agreement Hanmi will receive an initial payment of USD 50 million and is entitled to potential milestone payments of USD 680 million plus tiered double-digit royalties on future net sales. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions.
In India Glenmark Pharmaceuticals has now introduced its new third generation oral anti diabetic agent Teneligliptin for type-2 diabetes at an affordable price of Rs. 19.90 per tablet. The first pan India launch of Teneligliptin under two brands: Ziten and Zita Plus took place in Bengaluru. The molecule gliptin comes under the category of DPP-4 inhibitors, which is backed by scientific data as being safe, well tolerated, weight neutral with low risk of hypoglycemia.
[adsense:336x280:8701650588]
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
